Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study

• Published in: Clinical rheumatology Vol. 36; no. 9; pp. 1989 - 1996
• Main Authors: Gaubitz, Markus, Göttl, Karl-Heinz, Behmer, Olaf, Lippe, Ralph, Meng, Thomas, Löschmann, Peter-Andreas
• Format: Journal Article
• Language: English
• Published: London Springer London 01.09.2017; Springer Nature B.V
• Subjects: Adult; Aged; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Clinical trials; Drug Therapy, Combination; Etanercept; Etanercept - therapeutic use; Female; Germany; Humans; Male; Medicine; Medicine & Public Health; Methotrexate; Methotrexate - therapeutic use; Middle Aged; Observational studies; Original Article; Prospective Studies; Receptors, Tumor Necrosis Factor - antagonists & inhibitors; Remission; Remission Induction; Rheumatoid arthritis; Rheumatology; Severity of Illness Index; Treatment Outcome; Observational study; Tumor necrosis factor-alpha; Etanercept; Methotrexate; Rheumatoid arthritis

Approximately 30% of patients with rheumatoid arthritis receiving biological disease-modifying antirheumatic drugs (bDMARDs) take them as monotherapy. Although etanercept (ETN) monotherapy has been evaluated in clinical trials, data in the real-world setting are sparse. We compared the efficacy and...